11 Luglio 2022
G Caldarola, M Galluzzo, N Bernardini, L Calabrese, M Grimaldi, G Moretta, G Pagnanelli, R G Shumak, M Talamonti, L Tofani, S Pallotta, K Peris, C Potenza, C De Simone, E Campione

Tildrakizumab in moderate-to-severe plaque psoriasis: A multicenter, retrospective, real-life study

Dermatol Ther. 2022 Jun;35(6):e15488
  • L’obiettivo del presente studio è stato quello di analizzare l’efficacia e la sicurezza di tildrakizumab, agente biologico diretto contro dell’asse interleuchina (IL)23/T-helper17, in una popolazione real-life di pazienti affetti da psoriasi moderata-severa in un periodo di trattamento di 28 settimane.
  • Tildrakizumab ha mostrato un’alta efficacia e un profilo di sicurezza favorevole, indipendentemente dai fattori legati al paziente e alla malattia.


New biologic agents targeting interleukin (IL)23/T-helper17 axis, such as tildrakizumab, have been developed for the treatment of plaque psoriasis. To analyze the efficacy and safety of tildrakizumab in a real life setting of patients affected by moderate-to-severe psoriasis over a 28-week treatment period. A multicentric retrospective study was conducted in patients who initiated tildrakizumab between February 2020 and March 2021. Psoriasis Area and Severity Index-PASI was measured at baseline and after 4, 16 and 28 weeks. The percentage change in PASI value from baseline to the considered time-points, proportion of patients with absolute PASI <3 at week 28 and the percentages of achieving a PASI75 or PASI90 response were assessed. Data about potential safety issues and adverse events (AEs) were collected. Statistical analysis were performed for establish clinical efficacy and for variables predicting clinical response. Fifty nine patients with psoriasis were included. Overall mean PASI percentage reduction was of 88% from baseline to week 28 and 47 out of 59 patients (79.7%) at week 28 had an absolute PASI <3. PASI75 and PASI90 responses at week 28 were achieved by 48 (81.40%) patients and 38 (64.4.0%) patients, respectively. No substantial associations between gender, body mass index – BMI, PASI at baseline and prior exposition to biological therapies and the efficacy endpoints were retrieved. No serious safety issues or discontinuations related to adverse events were reported. In our real-life study, tildrakizumab showed high efficacy and a favorable safety profile, regardless of patient- and disease-related factors.

Tagged on:
Accedi all’abstract originale